| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5824603 | Clinical Therapeutics | 2015 | 9 Pages |
Abstract
Extensive clinical evidence supports the use of CTLA-4-targeted agents in the treatment of metastatic melanoma. The durability of response seen in patients receiving these agents has changed the landscape for patients with melanoma. Combination therapies and other agents with similar mechanisms warrant further exploration for the treatment of metastatic melanoma.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Elizabeth I. MD, David F. MD,